Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026
Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Drug

Juventas Cell Therapy Secures China Clinical Trial Approval for Inaticabtagene Autoleucel in AIHA

Fineline Cube Apr 11, 2025

Chinese firm Juventas Cell Therapy Ltd has obtained tacit clinical trial approval in China for...

Company Drug

Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy

Fineline Cube Apr 11, 2025

China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...

Company Drug

Zai Lab’s Partner argenx Secures FDA Approval for Vygart Hytrulo Prefilled Syringe in gMG and CIDP

Fineline Cube Apr 11, 2025

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) and its Dutch partner argenx SE (NASDAQ:...

Company Deals

Pierre Fabre and RedRidge Bio Partner on Biparatopic Antibody Development for Precision Oncology

Fineline Cube Apr 11, 2025

France’s Pierre Fabre Laboratories has entered into a strategic partnership with Switzerland-based RedRidge Bio AG...

Company Deals Medical Device

INTCO Medical and JD Healthcare Partner to Innovate ‘Internet + Healthcare’ Service Models

Fineline Cube Apr 11, 2025

China-based INTCO Medical (SHE: 300677), a high-tech manufacturer of medical consumables and equipment, has entered...

Company Medical Device

KingstronBio’s Prostyle A Valve Gains NMPA Approval, Setting New Benchmark in Transcatheter Aortic Valve Replacement

Fineline Cube Apr 11, 2025

KingstronBio, a Changshu-based structural heart disease device manufacturer, has obtained marketing approval from China’s National...

Company Deals

iRegene Therapeutics Secures RMB 100 Million in Series B+ Financing to Advance iPSC Technology

Fineline Cube Apr 11, 2025

Wuhan-based iRegene Therapeutics, a pioneer in AI-powered, chemically induced cell therapies, has reportedly raised close...

Company

Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs

Fineline Cube Apr 11, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...

Company Drug

Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment

Fineline Cube Apr 11, 2025

China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...

Company Deals

Nona Biosciences and Atossa Therapeutics Forge Partnership to Advance Breast Cancer Therapies

Fineline Cube Apr 11, 2025

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Drug

Bayer’s Vitrakvi Fully Approved by FDA for NTRK Fusion Solid Tumors

Fineline Cube Apr 11, 2025

Germany-based Bayer (ETR: BAYN) announced that it has received full approval from the US Food...

Company Drug

Luye Pharma Launches Rotigotine Luye in UK for Parkinson’s and Restless Leg Syndrome

Fineline Cube Apr 11, 2025

China-based Luye Pharma Group (HKG: 2186) announced the market launch of Rotigotine Luye in the...

Company Deals

Astellas Pharma Partners with Shanghai Pharma on Zolbetuximab Commercialization

Fineline Cube Apr 11, 2025

Japan-based Astellas Pharma Inc. (TYO: 4503) announced a strategic partnership with Shanghai Pharmaceuticals (SPH; SHA:...

Company Drug

CK Life Sciences Reports Promising Preclinical Results for TROP2-Targeted Cancer Vaccine

Fineline Cube Apr 11, 2025

China-based CK Life Sciences (HKG: 0775) has announced positive early results from preclinical studies of...

Company Drug

Kangtai Biological’s Pentavalent Rotavirus Vaccine Enters Phase III Trials

Fineline Cube Apr 10, 2025

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) announced the enrollment of the first patient...

Company Drug

Zelgen Biopharma’s ZG005 Approved for Gastrointestinal Tumor Trials in China

Fineline Cube Apr 10, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received approval from China’s...

Company Drug

HemaCell’s XJ-MK-002 Gains FDA Orphan Drug Designation for Giant Platelet Syndrome

Fineline Cube Apr 10, 2025

China-based Suzhou Xueji Biotechnology Co., Ltd (HemaCell), a pioneer in platelet regeneration-focused cell therapy, announced...

Company Drug

IVIEW Therapeutics’ IVIEW-1201 Gains FDA Orphan Drug Designation for Fungal Keratitis

Fineline Cube Apr 10, 2025

China-based IVIEW Therapeutics Inc. announced that it has received Orphan Drug Designation (ODD) from the...

Company Drug

Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China

Fineline Cube Apr 10, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis

Fineline Cube Apr 10, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Posts pagination

1 … 121 122 123 … 608

Recent updates

  • RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones
  • Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China
  • Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab
  • Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations
  • SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.